Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Bibikova E, Parsa S, Floren M, Law B, Clevenger T, Cheung J, De Jesus G, Burke K, Gulrajani M, Yamaguchi K, Do P, Dougherty B, Whitston D, Brock G, Munugalavadla V, Frigault MM, Hartmann TN, Byrd JC, Furman RR, Brown JR, Covey T, Mortlock A. Bibikova E, et al. Among authors: furman rr. Hematol Oncol. 2025 Jan;43(1):e70008. doi: 10.1002/hon.70008. Hematol Oncol. 2025. PMID: 39716442
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis.
Kleinstern G, Boddicker NJ, O'Brien DR, Allmer C, Rabe KG, Norman AD, Griffin R, Yan H, Ma T, Call TG, Bruins L, Brown S, Bonolo de Campos C, Hanson CA, Leis JF, Ding W, Vachon CM, Kay NE, Oakes CC, Parker AS, Brander DM, Weinberg JB, Furman RR, Shanafelt TD, Cerhan JR, Parikh SA, Braggio E, Slager SL. Kleinstern G, et al. Among authors: furman rr. Blood Adv. 2024 May 14;8(9):2118-2129. doi: 10.1182/bloodadvances.2023012242. Blood Adv. 2024. PMID: 38359367 Free PMC article.
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, Di Siervi N, Lara-Garcia J, Allan JN, Ruan J, Furman RR, Chen Z, Shore TB, Phillips AA, Mayer S, Hsu J, van Besien K, Leonard JP, Borden KLB, Inghirami G, Martin P, Cerchietti L. Marullo R, et al. Among authors: furman rr. Cancer Res. 2024 Jan 2;84(1):101-117. doi: 10.1158/0008-5472.CAN-23-1992. Cancer Res. 2024. PMID: 37801604 Free PMC article.
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Chong SJF, et al. Among authors: furman rr. J Clin Invest. 2023 Nov 15;133(22):e170169. doi: 10.1172/JCI170169. J Clin Invest. 2023. PMID: 37751299 Free PMC article.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Seymour JF, et al. Among authors: furman rr. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy.
Arruga F, Rubin M, Papazoglou D, Iannello A, Ioannou N, Moia R, Rossi D, Gaidano G, Coscia M, Laurenti L, D'Arena G, Allan JN, Furman RR, Vaisitti T, Ramsay AG, Deaglio S. Arruga F, et al. Among authors: furman rr. Haematologica. 2023 Aug 1;108(8):2101-2115. doi: 10.3324/haematol.2022.282177. Haematologica. 2023. PMID: 36655432 Free PMC article.
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
Sharma S, Pepin X, Burri H, Zheng L, Kuptsova-Clarkson N, de Jong A, Yu T, MacArthur HL, Majewski M, Byrd JC, Furman RR, Ware JA, Mann J, Ramies D, Munugalavadla V, Sheridan L, Tomkinson H. Sharma S, et al. Among authors: furman rr. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1294-1307. doi: 10.1002/cpdd.1153. Epub 2022 Aug 27. Clin Pharmacol Drug Dev. 2022. PMID: 36029150 Free PMC article.
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K, Kipps TJ, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thurston AW, Sun M, Schmidt EM, Lannutti BJ, Johnson DM, Miller LL, Spurgeon SE. Wang ML, et al. Among authors: furman rr. NEJM Evid. 2022 Jan;1(1):EVIDoa2100001. doi: 10.1056/EVIDoa2100001. Epub 2021 Oct 12. NEJM Evid. 2022. PMID: 38319241
167 results